| Literature DB >> 28845185 |
Mateusz Wojciech Romanowski1,2, Maja Špiritović3, Radosław Rutkowski4, Adrian Dudek1, Włodzimierz Samborski1, Anna Straburzyńska-Lupa2,4.
Abstract
OBJECTIVES: This study aims to compare the effectiveness of deep tissue massage (DTM) and therapeutic massage (TM) in the management of ankylosing spondylitis (AS) patients.Entities:
Year: 2017 PMID: 28845185 PMCID: PMC5563410 DOI: 10.1155/2017/9894128
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Criteria for inclusion and exclusion.
| Inclusion in the study | Exclusion from the study |
|---|---|
| Diagnosis of AS | Change in dosage of nonsteroidal anti-inflammatory drugs and corticosteroids for 2 weeks before the beginning of the study and for the duration of the study |
Figure 1Trial profile.
Baseline characteristics of the 27 patients with ankylosing spondylitis.
| DTM group ( | TM group ( |
| |
|---|---|---|---|
| Age (years) | 49 (7.78) | 45 (6.71) | 0.351 |
| ESR (mm/h) | 26.1 (8.07) | 27.3 (11.71) | 0.758 |
| CRP (mg/l) | 27.0 (9.41) | 28.9 (12.56) | 0.418 |
| BMI | 27.9 (2.63) | 31.4 (11.64) | 0.394 |
| BASDAI [NRS] | 6.9 (1.45) | 6.7 (0.89) | 0.763 |
| BASFI [NRS] | 6.2 (1.23) | 5.7 (1.56) | 0.274 |
| CE [cm] | 1.6 (0.49) | 1.3 (0.81) | 0.188 |
| MS [cm] | 1.5 (0.83) | 1.7 (1.44) | 0.380 |
| FTF [cm] | 20.56 (9.96) | 19.23 (7.39) | 0.460 |
| PAIN [VAS] | 69.8 (12.51) | 63.3 (10.49) | 0.107 |
|
| |||
| NSAID | 12 | 11 | |
| DMARD synthetic | 9 | 8 | |
| DMARD biologics | 1 | 1 | |
The results are expressed as mean (SD); BMI: body mass index.; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; CE: chest expansion; MS: Modified Schober; FTF: Finger to Floor; PAIN: intensity of lower back pain; NRS: numerical rating scale; VAS: Visual Analog Scale; NSAID: nonsteroidal anti-inflammatory drugs; DMARDs: disease-modifying antirheumatic drugs; p values for differences in the baseline data between the DTM and the TM groups.
Mean score differences over time according to group allocation using intention to treat analysis.
| DTM group ( | TM group ( | The difference in change between the groups | Effect size | Both groups | |
|---|---|---|---|---|---|
| Change in DTM group | Change in TM group |
| |||
| BASDAI [NRS] | −1.21 (−1.82 to −0.61) | −0.68 (−0.84 to −0.53) | −0.53 (−1.14 to 0.08) | 0.69 | 0.021 |
| BASFI [NRS] | −0.50 (−0.88 to −0,12) | −0.35 (−0.49 to −0.20) | −0.15 (−0.56 to 0.26) | 0.31 | 0.896 |
| CE [cm] | 0.32 (0.11 to 0.54) | 0.31 (0.08 to 0.54) | 0.01 (−0.29 to 0.31) | 0.03 | 0.915 |
| MS [cm] | 0.57 (0.47 to 0.68) | 0.50 (0.25 to 0.75) | 0.07 (−0.16 to 0.30) | 0.22 | 0.328 |
| FTF [cm] | −2.57 (−3.11 to −2.03) | −2.19 (−2.53 to −1.85) | −0.38 (−0.99 to 0.24) | 0.49 | 0.222 |
| PAIN [VAS] | −35.21 (−45.19 to −25.23) | −15.23 (−22.20 to −8.25) | −19.98 (−31.74 to −8.23) | 1.36 | 0.003 |
BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; CE: chest expansion; MS: Modified Schober; FTF: Finger to Floor; PAIN: intensity of lower back pain; NRS: numerical rating scale; VAS: Visual Analog Scale; p values for differences in the changed score between the baseline and the posttherapy data between the DTM and the TM groups.